There are currently 295 active clinical trials seeking participants for Prostate Cancer research studies. The states with the highest number of trials for Prostate Cancer participants are California, New York, Texas and Ohio.
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
NCT03769766
Recruiting
This is a prospective study to determine if the use of curcumin randomized against placebo will reduce cancer progression in patients with prostate cancer undergoing active surveillance.
Gender:
MALE
Ages:
Between 40 years and 89 years
Trial Updated:
12/09/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Prostate Cancer
Register for Updates
A Study of a Pelvic Floor Muscle Exercise Program Before and After Radical Prostatectomy
NCT06671782
Recruiting
The researchers are doing this study to find out if a PFME program to reduce urinary incontinence after radical prostatectomy is feasible for people with prostate cancer. The researchers will track how many participants join the study, follow the program, and stay in the study. They will also evaluate how people feel about their experience and satisfaction with participating in this program through interviews. They will also measure participants' quality of life by filling out questionnaires, an... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Prostate Cancer
Register for Updates
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
NCT05804318
Recruiting
This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California +3 locations
Conditions: Prostate Cancer
Register for Updates
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
NCT06451497
Recruiting
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Pembrolizumab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/29/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +2 locations
Conditions: Non Small Cell Lung Cancer, Esophageal Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer, Prostate Cancer, Urothelial Carcinoma, Colorectal Cancer, Triple Negative Breast Cancer, High Grade Ovarian Serous Adenocarcinoma, Diffuse Large B Cell Lymphoma
Register for Updates
Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)
NCT06705803
Recruiting
Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer of men in the world. In 2023 alone, it is estimated that 288,300 US men will be diagnosed with prostate cancer and 34,700 will die from the disease despite the approval of multiple systemic agents. Due to advances in screening and imaging technology, PCa is now detected much earlier in its disease course. Prostate gland ablation for prostate cancer might provide the option for a "middle" ground between active surveillance... Read More
Gender:
MALE
Ages:
22 years and above
Trial Updated:
11/22/2024
Locations: The University of Chicago, Hyde Park, Illinois +1 locations
Conditions: Prostate Cancer
Register for Updates
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
NCT04808427
Recruiting
Background: The ability to treat early prostate cancer is still limited. Thermal ablation methods are being tested for focal prostate cancer therapy. Researchers want to improve on these methods. Objective: To understand if Transurethral UltraSound Ablation (TULSA) in combination with MRI guidance is useful to treat localized prostate cancer. Eligibility: English-speaking adults ages 18 and older with localized prostate cancer that can be seen on MRI and can be treated by thermal ablation.... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostate Cancer
Register for Updates
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
NCT03151629
Recruiting
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingd... Read More
Gender:
MALE
Ages:
21 years and above
Trial Updated:
11/21/2024
Locations: University of Alabama-Birmingham, Birmingham, Alabama +120 locations
Conditions: Prostate Cancer
Register for Updates
Video Education With Result Dependent dIsclosure
NCT05225428
Recruiting
The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Genetic Testing, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Colorectal Cancer, Renal Cancer, Melanoma, Sarcoma
Register for Updates
Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)
NCT05345444
Recruiting
This is a single-site trial for 42 subjects with intermediate risk prostate cancer who undergo Irreversible Electroporation (IRE) followed by Magnetic Resonance guided Radiotherapy MRgRT. The investigators hypothesize that the combined therapy will feasible and be safe to perform with low morbidity. Ultimately, RTIRE may provide optimal treatment for intermediate risk prostate cancer patients.
Gender:
MALE
Ages:
Between 18 years and 99 years
Trial Updated:
11/20/2024
Locations: Weill Cornell Medicine, New York, New York
Conditions: Prostate Cancer
Register for Updates
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
NCT06391034
Recruiting
This is a Phase 2 clinical study of hyperpolarized (HP) 13C-pyruvate (13C), 15N-urea (13C,15N) metabolic MR imaging in prostate cancer patients who are undergoing or have received radiation therapy for prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Prostate Cancer
Register for Updates
UFPTI 2403-PR12: Real-Time Volumetric Ionizing Radiation Acoustic Imaging for In-vivo Proton Treatment Monitoring in Pencil-Beam Scanning
NCT06465966
Recruiting
The purpose of this study is to evaluate the use of ionizing-radiation photo acoustic imaging (iRAI) for proton radiation treatment.
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
11/13/2024
Locations: Univeristy of Florida Health Proton Therapy Institute, Jacksonville, Florida
Conditions: Prostate Cancer
Register for Updates
Customized TULSA-PRO Ablation Registry
NCT05001477
Recruiting
This patient registry will capture data from patients who have been or who are undergoing the transurethral ultrasound ablation (TULSA) procedure as part of their routine clinical care. The registry will shed light on real-world outcomes of safety and efficacy of the procedure and understand how a patient's quality of life is affected throughout their follow-up and lifetime.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: RadNet's Liberty Pacific West Hills Facility, West Hills, California +4 locations
Conditions: Prostate Cancer, Prostate Adenocarcinoma, Benign Prostatic Hyperplasia
Register for Updates